OncoMatch

OncoMatch/Clinical Trials/NCT04868149

Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS

Is NCT04868149 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for liver cancer.

Phase 3RecruitingThe University of Hong KongNCT04868149Data as of May 2026

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a new surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed. This surgical procedure was incepted in Germany in 2013 and was later started in Queen Mary Hospital in Hong Kong for the first time in December 2015. The initial indication was mainly for colorectal liver metastasis but due to the relatively high incidence of hepatocellular carcinoma in Hong Kong, HBP surgery team of Queen Mary Hospital has transferred this procedure to be applied for hepatitis-related hepatocellular carcinoma and so far, the centre has cumulated one of the largest single-center experience in the literature. Nonetheless, the usual approach for ALPPS involved open surgery and induced substantial surgical stress to the patient, especially after stage I operation. With the advent of minimally invasive liver surgery in recent years, the team has successfully applied laparoscopic surgery to ALPPS in 2019. Despite the advancement in laparoscopic surgical skills that rendered laparoscopic ALPPS feasible, there is scarcity of data in the literature to evaluate its outcome in comparison with open ALPPS with regard to perioperative recovery and liver regeneration. Hence, the aim of this project is to evaluate the short-term clinical outcomes of laparoscopic ALPPS and the impact of laparoscopy on liver remnant regeneration after ALPPS in a prospective randomised clinical trial setting.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

Platelet count > 100x10^9/L

Liver function

Child A cirrhosis (due to hepatitis B/C virus, or alcohol, or autoimmune disease); Indocyanine green clearance rate at 15 mins < 18%

Child A cirrhosis (due to hepatitis B/C virus, or alcohol, or autoimmune disease); Indocyanine green clearance rate at 15 mins < 18%; Platelet count > 100x10^9/L

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify